Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00004368

Enrollment

Registered

1999-10-19

Start date

1990-05-31

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver Cirrhosis

Keywords

hepatic cirrhosis, gastrointestinal disorders, rare disease

Brief summary

OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.

Detailed description

PROTOCOL OUTLINE: Patients receive colchicine orally twice daily for 24 months. After the first month, the dose of colchicine will increase and remain at that dose for the duration of study. Patients are evaluated every 6 months during study.

Interventions

DRUGcolchicine

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

0 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Advanced hepatic fibrosis or cirrhosis in children * Not pregnant

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026